MZN.F : Summary for MEDICINES CO. DL-,001 - Yahoo Finance

U.S. Markets closed

The Medicines Company (MZN.F)


Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
32.57+1.57 (+5.06%)
At close: 9:36 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close31.00
Open30.29
Bid32.92 x 20000
Ask33.07 x 20000
Day's Range30.29 - 32.57
52 Week Range25.22 - 37.07
Volume105
Avg. Volume6
Market Cap2.19B
BetaN/A
PE Ratio (TTM)-11.19
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Lexmark International Inc (LXK) A Good Stock To Buy Right Now?
    Insider Monkey5 days ago

    Is Lexmark International Inc (LXK) A Good Stock To Buy Right Now?

    Billionaire hedge fund managers such as Steve Cohen and Stan Druckenmiller can generate millions or even billions of dollars every year by pinning down high-potential small-cap stocks and pouring cash into these candidates. Small-cap stocks are overlooked by most investors, brokerage houses, and financial services hubs, while the unlimited research abilities of the big players […]

  • Hedge Funds Are Betting On The Medicines Company (MDCO)
    Insider Monkey7 days ago

    Hedge Funds Are Betting On The Medicines Company (MDCO)

    Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]

  • Reuters24 days ago

    Long-lasting cholesterol lowering seen with Medicines Co drug -study

    A new type of heart drug developed by Medicines Co significantly lowered "bad" LDL cholesterol in high-risk patients with no major safety issues, according to data from a midstage trial that helped the company identify the dose it will move into advanced testing. The study tested several strengths of inclisiran against a placebo in about 500 patients, many of whom had had a prior heart attack or stroke. The study found 300 milligrams to be the minimum dose to achieve maximum efficacy, having shown itself to lower LDL about as much as the 500 mg strength.